
Opinion|Videos|December 2, 2024
Neurokinin and Estrogen Balance in Menopausal Hot Flashes for Primary Care
Panelists discuss how to simplify the physiology of KNDy neurons and neurokinin (NK) receptors for primary care physicians, explaining how NK3 antagonism reduces hot flashes, while NK1 antagonism helps alleviate sleep disturbances and night sweats, with fezolinetant and elinzanetant serving as key nonhormonal treatment options.
Advertisement
Episodes in this series

- How can we simplify the physiology of KNDY neurons and roles of NK receptors for better understanding among primary care physicians?
Note: NK3 antagonism targets VMS (hot flashes); NK1 antagonism impacts sleep and night sweats
Note: Fezolinetant, a selective NK3 antagonist, reduces hot flashes
Note: Elinzanetant, in addition to reducing hot flashes (via NK3 antagonism) is also an NK1 antagonist which improves sleep disturbances and night sweats
Advertisement
Related to this article

Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.

HRSA will award up to $1 million to a single organization to update the Women's Preventive Services Guidelines through the new WISH program.

Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.

Soma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.

CMS' proposed G-codes, which experts stated would cause confusion in combination with the AMA's proposed codes, were not included in the final fee schedule for 2027, according to ACOG.

Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.

Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Centers for Medicare, Medicaid Services includes AMA's obstetric codes in 2027 fee schedule
2
Diagnosing Sleep Disturbances Beyond VMS in Menopause
3
Reactions to FDA's boxed warning removals for menopausal hormone therapy
4
Top video interviews from The Menopause Society 2026 Annual Meeting
5

